FDA label a49aeba4-17cd-48d1-e053-2a95a90a39fb

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
1ba3f528-4d46-4cb4-ba3e-103e01d79573
SPL ID
a49aeba4-17cd-48d1-e053-2a95a90a39fb
Version
3
Effective date
2020-05-01
Source export date
2026-11-13
Source partition
4
Source file
https://download.open.fda.gov/drug/label/drug-label-0004-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/2aa9706206c534e56285cf80077b2cca2320f0a236e2aa30e80d064749f7c888/drug-label-0004-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 15:54:10

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Drug-induced hepatitis (e.g., acute hepatitis, cytolytic hepatitis) has been reported with PREZISTA/ritonavir. Monitor liver function before and during therapy, especially in patients with underlying chronic hepatitis, cirrhosis, or in patients who have pre-treatment elevations of transaminases. Post-marketing cases of liver injury, including some fatalities, have been reported. ( 5.2 ) Skin reactions ranging from mild to severe, including Stevens-Johnson Syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms and acute generalized exanthematous pustulosis, have been reported. Discontinue treatment if severe reaction develops. ( 5.3 ) Use with caution in patients with a known sulfonamide allergy. ( 5.4 ) Patients may develop new onset diabetes mellitus or hyperglycemia. Initiation or dose adjustments of insulin or oral hypoglycemic agents may be required. ( 5.6 ) Patients may develop redistribution/accumulation of body fat or immune reconstitution syndrome. ( 5.7 , 5.8 ) Patients with hemophilia may develop increased bleeding events. ( 5.9 ) PREZISTA/ritonavir is not recommended in pediatric patients below 3 years of age in view of toxicity and mortality observed in juvenile rats dosed with darunavir up to days 23 to 26 of age. ( 5.10 ) 5.1 Importance of Co-administration with Ritonavir PREZISTA must be co-administered with ritonavir and food to achieve the desired antiviral effect. Failure to administer PREZISTA with ritonavir and food may result in a loss of efficacy of darunavir. Please refer to ritonavir prescribing information for additional information on precautionary measures. 5.2 Hepatotoxicity Drug-induced hepatitis (e.g., acute hepatitis, cytolytic hepatitis) has been reported with PREZISTA/ritonavir. During the clinical development program (N=3063), hepatitis was reported in 0.5% of patients receiving combination therapy with PREZISTA/ritonavir. Patients with pre-existing liver dysfunction, including chronic active hepatitis B or C, have an increased risk for liver function abnormalities including severe hepatic adverse events. Post-marketing cases of liver injury, including some fatalities, have been reported. These have generally occurred in patients with advanced HIV-1 disease taking multiple concomitant medications, having co-morbidities including hepatitis B or C co-infection, and/or developing immune reconstitution syndrome. A causal relationship with PREZISTA/ritonavir therapy has not been established. Appropriate laboratory testing should be conducted prior to initiating therapy with PREZISTA/ritonavir and patients should be monitored during treatment. Increased AST/ALT monitoring should be considered in patients with underlying chronic hepatitis, cirrhosis, or in patients who have pre-treatment elevations of transaminases, especially during the first several months of PREZISTA/ritonavir treatment. Evidence of new or worsening liver dysfunction (including clinically significant elevation of liver enzymes and/or symptoms such as fatigue, anorexia, nausea, jaundice, dark urine, liver tenderness, hepatomegaly) in patients on PREZISTA/ritonavir should prompt consideration of interruption or discontinuation of treatment. 5.3 Severe Skin Reactions During the clinical development program (n=3063), severe skin reactions, accompanied by fever and/or elevations of transaminases in some cases, have been reported in 0.4% of subjects. Stevens-Johnson Syndrome was rarely (less than 0.1%) reported during the clinical development program. During post-marketing experience toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms, and acute generalized exanthematous pustulosis have been reported. Discontinue PREZISTA/ritonavir immediately if signs or symptoms of severe skin reactions develop. These can include but are not limited to severe rash or rash accompanied with fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, hepatitis and/or eosinophilia. Rash (all grades, regardless of causality) occurred in 10.3% of subjects treated with PREZISTA/ritonavir [ also see Adverse Reactions (6) ] . Rash was mostly mild-to-moderate, often occurring within the first four weeks of treatment and resolving with continued dosing. The discontinuation rate due to rash in subjects using PREZISTA/ritonavir was 0.5%. Rash occurred more commonly in treatment-experienced subjects receiving regimens containing PREZISTA/ritonavir + raltegravir compared to subjects receiving PREZISTA/ritonavir without raltegravir or raltegravir without PREZISTA/ritonavir. However, rash that was considered drug related occurred at similar rates for all three groups. These rashes were mild to moderate in severity and did not limit therapy; there were no discontinuations due to rash. 5.4 Sulfa Allergy Darunavir contains a sulfonamide moiety. PREZISTA should be used with caution in patients with a known sulfonamide allergy. In clinical studies with PREZISTA/ritonavir, the incidence and severity of rash were similar in subjects with or without a history of sulfonamide allergy. 5.5 Risk of Serious Adverse Reactions due to Drug Interactions Initiation of PREZISTA/ritonavir, a CYP3A inhibitor, in patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving PREZISTA/ritonavir, may increase plasma concentrations of medications metabolized by CYP3A. Initiation of medications that inhibit or induce CYP3A may increase or decrease concentrations of PREZISTA/ritonavir, respectively. These interactions may lead to: Clinically significant adverse reactions, potentially leading to severe, life threatening, or fatal events from greater exposures of concomitant medications. Clinically significant adverse reactions from greater exposures of PREZISTA/ritonavir. Loss of therapeutic effect of PREZISTA/ritonavir and possible development of resistance. See Table 11 for steps to prevent or manage these possible and known significant drug interactions, including dosing recommendations [see Drug Interactions (7) ] . Consider the potential for drug interactions prior to and during PREZISTA/ritonavir therapy; review concomitant medications during PREZISTA/ritonavir therapy; and monitor for the adverse reactions associated with the concomitant drugs [see Contraindications (4) and Drug Interactions (7) ] . 5.6 Diabetes Mellitus/Hyperglycemia New onset diabetes mellitus, exacerbation of pre-existing diabetes mellitus, and hyperglycemia have been reported during postmarketing surveillance in HIV-infected patients receiving protease inhibitor (PI) therapy. Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. In some cases, diabetic ketoacidosis has occurred. In those patients who discontinued PI therapy, hyperglycemia persisted in some cases. Because these events have been reported voluntarily during clinical practice, estimates of frequency cannot be made and causal relationships between PI therapy and these events have not been established. 5.7 Fat Redistribution Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and "cushingoid appearance" have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established. 5.8 Immune Reconstitution Syndrome Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including PREZISTA. During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection, cytomegalovirus, Pneumocystis jirovecii pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment. Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barré syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of antiretroviral treatment. 5.9 Hemophilia There have been reports of increased bleeding, including spontaneous skin hematomas and hemarthrosis in patients with hemophilia type A and B treated with PIs. In some patients, additional factor VIII was given. In more than half of the reported cases, treatment with PIs was continued or reintroduced if treatment had been discontinued. A causal relationship between PI therapy and these episodes has not been established. 5.10 Not Recommended in Pediatric Patients Below 3 Years of Age PREZISTA/ritonavir in pediatric patients below 3 years of age is not recommended in view of toxicity and mortality observed in juvenile rats dosed with darunavir (from 20 mg/kg to 1000 mg/kg) up to days 23 to 26 of age [see Use in Specific Populations (8.1 and 8.4) and Clinical Pharmacology (12.3) ] .

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 2 of 2 · 5 matching rows.

adverse reactions table

<table width="85%" ID="table10"> <caption>Table 10: Grade 2 to 4 Laboratory Abnormalities Observed in Antiretroviral Treatment-Experienced HIV-1-Infected Adult Subjects <footnote ID="K3047">Grade 4 data not applicable in Division of AIDS grading scale</footnote> (Trial TMC114-C214) </caption> <col width="30%" valign="top" align="left"/> <col width="30%" valign="top" align="center"/> <col width="20%" valign="top" align="center"/> <col width="20%" valign="top" align="center"/> <thead> <tr> <th styleCode="Lrule Rrule" valign="bottom">Laboratory parameter, % </th> <th align="center" styleCode="Rrule" valign="bottom">Limit</th> <th styleCode="Rrule" valign="bottom">PREZISTA/ritonavir 600/100 mg twice daily + OBR</th> <th styleCode="Rrule" valign="bottom">lopinavir/ritonavir 400/100 mg twice daily + OBR</th> </tr> </thead> <tfoot> <tr> <td colspan="4" align="left">N=total number of subjects per treatment group; OBR=optimized background regimen</td> </tr> </tfoot> <tbody> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> <content styleCode="bold">Biochemistry</content> </td> <td styleCode="Rrule"/> <td styleCode="Rrule"/> <td styleCode="Rrule"/> </tr> <tr styleCode="Botrule"> <td colspan="4" styleCode="Lrule Rrule">Alanine Aminotransferase</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Grade 2</td> <td styleCode="Rrule">&gt;2.5 to &#x2264;5.0 &#xD7; ULN</td> <td styleCode="Rrule">7%</td> <td styleCode="Rrule">5%</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Grade 3</td> <td styleCode="Rrule">&gt;5.0 to &#x2264;10.0 &#xD7; ULN</td> <td styleCode="Rrule">2%</td> <td styleCode="Rrule">2%</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Grade 4</td> <td styleCode="Rrule">&gt;10.0 &#xD7; ULN</td> <td styleCode="Rrule">1%</td> <td styleCode="Rrule">2%</td> </tr> <tr styleCode="Botrule"> <td colspan="4" styleCode="Lrule Rrule">Aspartate Aminotransferase</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Grade 2</td> <td styleCode="Rrule">&gt;2.5 to &#x2264;5.0 &#xD7; ULN</td> <td styleCode="Rrule">6%</td> <td styleCode="Rrule">6%</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Grade 3</td> <td styleCode="Rrule">&gt;5.0 to &#x2264;10.0 &#xD7; ULN</td> <td styleCode="Rrule">2%</td> <td styleCode="Rrule">2%</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Grade 4</td> <td styleCode="Rrule">&gt;10.0 &#xD7; ULN</td> <td styleCode="Rrule">&lt;1%</td> <td styleCode="Rrule">2%</td> </tr> <tr styleCode="Botrule"> <td colspan="4" styleCode="Lrule Rrule">Alkaline Phosphatase</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Grade 2</td> <td styleCode="Rrule">&gt;2.5 to &#x2264;5.0 &#xD7; ULN</td> <td styleCode="Rrule">&lt;1%</td> <td styleCode="Rrule">0%</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Grade 3</td> <td styleCode="Rrule">&gt;5.0 to &#x2264;10.0 &#xD7; ULN</td> <td styleCode="Rrule">&lt;1%</td> <td styleCode="Rrule">&lt;1%</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Grade 4</td> <td styleCode="Rrule">&gt;10.0 &#xD7; ULN</td> <td styleCode="Rrule">0%</td> <td styleCode="Rrule">0%</td> </tr> <tr styleCode="Botrule"> <td colspan="4" styleCode="Lrule Rrule">Hyperbilirubinemia</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Grade 2</td> <td styleCode="Rrule">&gt;1.5 to &#x2264;2.5 &#xD7; ULN</td> <td styleCode="Rrule">&lt;1%</td> <td styleCode="Rrule">2%</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Grade 3</td> <td styleCode="Rrule">&gt;2.5 to &#x2264;5.0 &#xD7; ULN</td> <td styleCode="Rrule">&lt;1%</td> <td styleCode="Rrule">&lt;1%</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Grade 4</td> <td styleCode="Rrule">&gt;5.0 &#xD7; ULN</td> <td styleCode="Rrule">&lt;1%</td> <td styleCode="Rrule">0%</td> </tr> <tr styleCode="Botrule"> <td colspan="4" styleCode="Lrule Rrule">Triglycerides</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Grade 2</td> <td styleCode="Rrule">5.65&#x2013;8.48 mmol/L 500&#x2013;750 mg/dL </td> <td styleCode="Rrule">10%</td> <td styleCode="Rrule">11%</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Grade 3</td> <td styleCode="Rrule">8.49&#x2013;13.56 mmol/L 751&#x2013;1200 mg/dL </td> <td styleCode="Rrule">7%</td> <td styleCode="Rrule">10%</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Grade 4</td> <td styleCode="Rrule">&gt;13.56 mmol/L &gt;1200 mg/dL </td> <td styleCode="Rrule">3%</td> <td styleCode="Rrule">6%</td> </tr> <tr styleCode="Botrule"> <td colspan="4" styleCode="Lrule Rrule">Total Cholesterol</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Grade 2</td> <td styleCode="Rrule">6.20&#x2013;7.77 mmol/L 240&#x2013;300 mg/dL </td> <td styleCode="Rrule">25%</td> <td styleCode="Rrule">23%</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Grade 3</td> <td styleCode="Rrule">&gt;7.77 mmol/L &gt;300 mg/dL </td> <td styleCode="Rrule">10%</td> <td styleCode="Rrule">14%</td> </tr> <tr styleCode="Botrule"> <td colspan="4" styleCode="Lrule Rrule">Low-Density Lipoprotein Cholesterol</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Grade 2</td> <td styleCode="Rrule">4.13&#x2013;4.90 mmol/L 160&#x2013;190 mg/dL </td> <td styleCode="Rrule">14%</td> <td styleCode="Rrule">14%</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Grade 3</td> <td styleCode="Rrule">&#x2265;4.91 mmol/L &#x2265;191 mg/dL </td> <td styleCode="Rrule">8%</td> <td styleCode="Rrule">9%</td> </tr> <tr styleCode="Botrule"> <td colspan="4" styleCode="Lrule Rrule">Elevated Glucose Levels</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Grade 2</td> <td styleCode="Rrule">6.95&#x2013;13.88 mmol/L 126&#x2013;250 mg/dL </td> <td styleCode="Rrule">10%</td> <td styleCode="Rrule">11%</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Grade 3</td> <td styleCode="Rrule">13.89&#x2013;27.75 mmol/L 251&#x2013;500 mg/dL </td> <td styleCode="Rrule">1%</td> <td styleCode="Rrule">&lt;1%</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Grade 4</td> <td styleCode="Rrule">&gt;27.75 mmol/L &gt;500 mg/dL </td> <td styleCode="Rrule">&lt;1%</td> <td styleCode="Rrule">0%</td> </tr> <tr styleCode="Botrule"> <td colspan="4" styleCode="Lrule Rrule">Pancreatic Lipase</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Grade 2</td> <td styleCode="Rrule">&gt;1.5 to &#x2264;3.0 &#xD7; ULN</td> <td styleCode="Rrule">3%</td> <td styleCode="Rrule">4%</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Grade 3</td> <td styleCode="Rrule">&gt;3.0 to &#x2264;5.0 &#xD7; ULN</td> <td styleCode="Rrule">2%</td> <td styleCode="Rrule">&lt;1%</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Grade 4</td> <td styleCode="Rrule">&gt;5.0 &#xD7; ULN</td> <td styleCode="Rrule">&lt;1%</td> <td styleCode="Rrule">0%</td> </tr> <tr styleCode="Botrule"> <td colspan="4" styleCode="Lrule Rrule">Pancreatic Amylase</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Grade 2</td> <td styleCode="Rrule">&gt;1.5 to &#x2264;2.0 &#xD7; ULN</td> <td styleCode="Rrule">6%</td> <td styleCode="Rrule">7%</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Grade 3</td> <td styleCode="Rrule">&gt;2.0 to &#x2264;5.0 &#xD7; ULN</td> <td styleCode="Rrule">7%</td> <td styleCode="Rrule">3%</td> </tr> <tr> <td styleCode="Lrule Rrule"> Grade 4</td> <td styleCode="Rrule">&gt;5.0 &#xD7; ULN</td> <td styleCode="Rrule">0%</td> <td styleCode="Rrule">0%</td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.